adult use cannabis – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Wed, 04 Oct 2023 17:11:42 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.5 Decibel Launches General Admission ‘Blinker’ Closed Loop Vape System https://mjshareholders.com/decibel-launches-general-admission-blinker-closed-loop-vape-system/ Wed, 04 Oct 2023 17:11:42 +0000 https://cannabisfn.com/?p=2974104

Ryan Allway

October 4th, 2023

News, Top News


CALGARY, ABOct. 4, 2023 /PRNewswire/ – Decibel Cannabis Company Inc. (the “Company” or “Decibel”) (TSXV: DB) (OTCQB: DBCCF), a leading manufacturer of cannabis ready to consume products, is pleased to announce the launch of General Admission ‘Blinker’ closed loop vape system of products. These products are expected to be available to order for licensed retailers in British Columbia the week of October 16th, in Ontario on October 19th, in Saskatchewan the week of October 23rd, in Alberta on November 3rd and in Manitoba by mid-November.

Decibel Cannabis Logo (CNW Group/Decibel Cannabis Company Inc.)
Decibel Cannabis Logo (CNW Group/Decibel Cannabis Company Inc.)

“Blinker positions Decibel to meet consumer demand for a better vape experience that delivers bold flavours, smart innovation, best-in-class airflow and superior reliability in performance” said Warren Matzelle, Chief Marketing and Product Officer. “The game-changing Blinker vape system features industry-leading innovation to address the many consumer pain points with existing vape products in today’s market.  Blinker lets the consumer focus on having an enjoyable, problem-free vape experience.”

Decibel welcomes you to discover more about the future of vaping with the General Admission Blinker closed loop vape system, please visit www.generaladmission.ca/blinker

The initial products expected to be launched for the General Admission Blinker system are:

  • Tiger Blood 0.95g vape pod
  • Peach Rizz 0.95g vape pod
  • 5 Loco 0.95g vape pod
  • Essentials Mixer Pack 4×0.28 vape pods
  • Social Sampler Pack 4×0.28g vape pods
  • Blinker Vape Battery

Key Highlights of the General Admission Blinker System include:

  • Large initial assortment of flavours and SKUs which consumers have shown to love in other formats like infused pre-rolls, 510 vape cartridges and edibles
  • Blinker vape pods will be line priced with existing General Admission 510 vape cartridges
  • Blinker vape batteries will be priced in-line with standard 510 batteries, making the system comparable in cost to the 510 system for consumers
  • Smart pod technology reduces common vape issues like, clogging and leaking, with best-in-class airflow, vapour production and flavour

About Decibel

Decibel is a consumer-focused cannabis company focused on delivering products that delight customers through a commitment to robust innovation and product quality. Leading brands General Admission, Qwest, and Vox are among its portfolio sold both across Canada and beginning to extend towards new countries to create a global footprint. Decibel operates a processing and manufacturing facility in Calgary, Alberta, and two cultivation facilities in Creston, British Columbia, and Battleford, Saskatchewan.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

In this news release, forward-looking statements relate to, among other things, the Company’s strategy, focus and values; the Company’s expectations of when the Blinker closed loop vape system of products will be available to order for licensed retailers in certain provinces; the anticipated benefits to be derived from the Blinker closed loop vape system of products; the initial products that are expected to be launched for the Blinker closed loop vape system; the expected MSRP of the Blinker vape batteries; Decibel’s expectations that the Blinker closed loop vape system will change the vape category; Decibel’s expectations with respect to the impact that the new product launch will have on the Company’s business; Decibel’s expectations regarding market, industry and consumer feedback related to the Blinker closed loop vape system; and other business plans and expectations.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: satisfaction of all international regulatory requirements, including applicable product testing; risks relating to delays; other regulatory changes and impacts; capital requirements; construction impacts; displacement requirements; global macro-economic events, conditions and factors; the ability to obtain and maintain licenses to retail cannabis products; review of the Company’s production facilities by Health Canada and maintenance of licenses (including any amendments thereto) from Health Canada in respect thereof; future legislative and regulatory developments involving cannabis, international export rules and regulations; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the labour market generally and the ability to access, hire and retain employees; general business, economic, competitive, political and social uncertainties; the delay or failure to receive board, regulatory or other approvals, including any approvals of the TSX Venture Exchange, as applicable; and the risk that the Blinker closed loop vape system of products may not be available to order for licensed retailers when anticipated in the provinces anticipated;

With respect to forward-looking statements contained in this news release, Decibel has made assumptions regarding, but not limited to: demand for Decibel’s products; Decibel’s ability to realize operational efficiencies and effect certain cost saving measures (including in the impact thereof); Decibel’s ability to enter new markets and industry verticals; Decibel’s ability to attract, develop and retain key personnel; Decibel’s ability to raise additional capital and to execute on its expansion plans; the timelines for new product launches, Decibel’s ability to continue investing in infrastructure and implement scalable controls, systems and processes to support its growth; the impact of competition; the changes and trends in Decibel’s industry or the global economy; the Company’s ability to generate sufficient cash flow from operations and obtain financing, if needed, on acceptable terms or at all; the general economic, financial market, regulatory and political conditions in which the Company operates; the ability of the Company to ship its products and maintain supply chain stability; consumer interest in the Company’s products; anticipated and unanticipated costs; government regulation of the Company’s activities and products; the timely receipt of any required regulatory approvals; the Company’s ability to conduct operations in a safe, efficient and effective manner; the Company’s construction plans and timeframe for completion of such plans; and the changes in laws, rules, regulations, and global standards.

There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, the Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

These forward-looking statements are made as of the date of this news release and the Company disclaims any intent or obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Sweet Dirt Launches Provisions Brand Featuring Cannabis Staples and Goods for Good Times™ https://mjshareholders.com/sweet-dirt-launches-provisions-brand-featuring-cannabis-staples-and-goods-for-good-times/ Thu, 09 Feb 2023 19:28:02 +0000 https://www.cannabisfn.com/?p=2972611

Ryan Allway

February 9th, 2023

News, Top News


Provisions Brand Features Clean Adult-Use Cannabis Affordably Priced for Consumers that View Cannabis as Essential to Well-Being

ELIOT, MaineFeb. 9, 2023 /PRNewswire/ — Sweet Dirt, a Maine-based, vertically integrated cannabis company, today announced the launch of its Provisions brand, offering a line of affordable, and sustainably grown premium cannabis offerings for the Maine adult-use market. Provisions will be available at Sweet Dirt’s retail stores in PortlandWatervilleRockland, and Bridgton before Valentine’s Day and will also be available via select adult-use cannabis retailers throughout the State.

More than just a cannabis brand, Provisions embarks on a philosophy that aims to inspire consumers to unearth joy and savor their life journey. During the COVID pandemic, the US cannabis industry recorded significant sales growth in nascent and mature recreational markets alike. In Maineadult-use cannabis sales nearly doubled from $82 million in 2021 to $159 million in 2022. Now, a year out from COVID, cannabis consumption continues to grow as people in all walks of life seek to better manage anxiety, induce sleep, and enhance experiences such as physical activities, creative endeavors, and more. Consumers have started to take the initiative and are redefining their perspectives, choices, and the times that call for cannabis – in some cases, making cannabis consumption a part of their daily routines.

“We hear from our customers that their lives can be complex, intense, and often stressful. Individually, and as a society, we will continue to be faced with rapidly changing unpredictable life circumstances,” said Amanda Abelmann, SVP of Operations for Sweet Dirt. “With Provisions, we wanted to bring our adult-use customers a brand that includes clean product, first and foremost, sustainably packaged and at a discovery price point – empowering customers to continue their personal journey and explore all facets of how they choose to live their lives.”

Organically-Grown, Premium Products
Provisions features Sweet Dirt’s own organically-grown flower, certified clean by the Maine Organic Farmers and Gardeners Association (MOFGA), and grown in Sweet Dirt’s 32,800 square foot greenhouse on the Company’s 9-acre campus in Eliot, Maine. The Provisions line includes packaged flower, pre-rolls, and cartridges, with other product categories to be added later this year. Strains such as Bucketlist, zStar Punch, and the nostalgia-inducing 90s OG are selected for their flavor, terpene profiles, and effects.

Sustainable Packaging
Like its customers, Sweet Dirt is committed to sustainability:

Provisions pre-rolls are packaged two .75g pre-rolled joints to a tube in discreet, certified child-resistant, plastic-free, home compostable tubes.

Provisions flower is packaged in bags manufactured in New England and are child-resistant, resealable, and made with films that can be recycled wherever PE film recycling streams are available.

Provisions Vape carts, to be released in March 2023, are sold in boxes made using certified wind power.

Sweet Dirt’s Provisions line-up builds on the Company’s continued commitment to product innovation and to working with our customers to find and develop the products they want most. In 2022, Pioneer Intelligence ranked Sweet Dirt a Top 5 ‘Women-Led Cannabis Brand‘ and the company has amassed a following throughout the Northeast by those who prioritize organically-grown, super-premium cannabis and sustainable packaging.

Learn more about Sweet Dirt and Provisions at www.sweetdirt.com.

About Sweet Dirt
Sweet Dirt is a Maine-based, vertically integrated cannabis company offering premium cannabis and cannabis-infused products. A focus on the creation of its proprietary soils and organic growing practices have earned the company the MOFGA (Maine Organic Farmer and Gardeners Association) ‘Certified Clean Cannabis’ (MC3) designation achieved by fewer than 1% of all licensed cannabis growers in Maine.

For additional information:
[email protected]
(207) 439-1600

SOURCE Sweet Dirt

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Sipp Industries Fulfills Order for Newly Released Delta-8 Sauces, Tea, Fruit Punch and Medicinal Pain Lotion https://mjshareholders.com/sipp-industries-fulfills-order-for-newly-released-delta-8-sauces-tea-fruit-punch-and-medicinal-pain-lotion/ Wed, 15 Jun 2022 14:38:16 +0000 https://www.cannabisfn.com/?p=2951020

Ryan Allway

June 15th, 2022

News, Top News


Products now on the shelves at retail locations with additional orders planned

COSTA MESA, CA, June 15, 2022 (GLOBE NEWSWIRE) — Sipp Industries, Inc. (OTC Pink: SIPC), a multifaceted corporation specializing in manufacturing, and distribution of commercial and consumer products in the cannabis industry, announces it has fulfilled orders for its full suite of products with new distribution partner, Nectar Ventures.  The Company also announces it has developed and manufactured a new line of Delta-8 (“D8”) infused sauces under the “Sauz” brand.

The Company recently completed its first production run of Major Hemp D8 Sweet Lemon Tea and Fruit Punch which will be placed in retail coolers throughout the south-central states with national distribution plans underway at additional distributors.

Sipp Industries also reports it officially fulfilled its first orders for the newly developed THC-infused pain lotion under the Aveina brand.  With Aveina being the first THC product launch it will exclusively be sold in dispensaries throughout the state of Oklahoma.

In April, Sipp Industries began the development and manufacturing process for its new line of Sauz D8 infused sauces.  Inspired from an inquiry with a large prospect, Sipp Industries developed a variety of D8 nano-infused sauce flavors including BBQ, Chipotle, Siracha, Buffalo and Steak.  These new 10oz sauces pack a powerful punch with 1,000mg of nano emulsified D8 providing an uplifting and euphoric eating experience with your favorite foods.

Sipp Industries is planning sampling events at BBQ competitions/cook-offs and other “canna-competitions” for edibles and beverages throughout the summer.  The Company is also pursuing brand ambassadors to penetrate the cannabis-infused cuisine market which has become extremely popular for celebrity chefs on Netflix shows such as Bong Appetite and Cooking on High.

Interim Chief Executive Officer, Jakob Jorgensen, stated, “This is a significant milestone for Sipp Industries as we launch our new lines of Delta-8 beverages, sauces, and pain creams.  We’re beyond pleased with the product quality and efficacy of our nano D8 and our customers will truly feel the difference.  With the manufacturing operations in place, our focus will continue to be on marketing events, order fulfillment and new distributor acquisition.”

About Sipp Industries, Inc.:

Sipp Industries is a multifaceted corporation specializing in manufacturing and distribution of commercial and consumer products in the cannabis industry.

Website: http://www.sippindustries.com
Facebook: https://www.facebook.com/SippIndustries
Twitter: @SippIndustries

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27a of the Securities Act of 1933, as amended and section 21e of the Securities and Exchange Act of 1934, as amended. Those statements include the intent, belief or current expectations of the Company and its management team.

Forward-looking statements are projections of events, revenues, income, future economics, research, development, reformulation, product performance or management’s plans and objectives for future operations. Some or all of the events or results anticipated by these forward-looking statements may not occur. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. Accomplishing the strategy described herein is significantly dependent upon numerous factors, many that are not in management’s control.

Contact:

Sipp Industries, Inc.
Investor Relations
[email protected]
949.220.0435

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Columbia Care Operationalizes Second Cultivation Facility in New Jersey and Expands Adult Use Hours at Both Garden State Cannabist Locations https://mjshareholders.com/columbia-care-operationalizes-second-cultivation-facility-in-new-jersey-and-expands-adult-use-hours-at-both-garden-state-cannabist-locations/ Tue, 07 Jun 2022 14:30:54 +0000 https://www.cannabisfn.com/?p=2950112

Ryan Allway

June 7th, 2022

News, Top News


The Second Cultivation and Production Facility in Vineland Adds Approximately 270,000 Square Feet of Cultivation and Production Capacity and Will Triple Available Canopy in Phase One

Recent Approvals Also Allow for Use of Post-Harvest Automation Equipment to More Efficiently Meet the Growing Adult Use and Medical Demand

NEW YORK–(BUSINESS WIRE)– Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), one of the largest and most experienced cultivators, manufacturers and providers of cannabis products in the U.S., announced today it has started operations in its new, approximately 270,000-square-foot cultivation and production facility in New Jersey, begun using post-harvest automation equipment, and expanded its adult use shopping hours at both of its Cannabist locations in Deptford and Vineland to the maximum number of hours allotted by the New Jersey Cannabis Regulatory Commission (CRC).

The Company received approval from the New Jersey CRC to commence operations at its second cultivation and production facility on May 25, 2022, along with the approval to begin using post-harvest automation equipment. The introduction of this equipment will reduce the “harvest to shelf” time for products, making it easier to meet the rapidly-growing patient and customer demand.

“After ten years of navigating the ever-evolving cannabis industry in various markets, we have so many lessons learned and have been able to bring those to bear in how we approach New Jersey, knowing how it will serve as a model for those east coast states transitioning to adult use in the near term. We are proud of how we managed to scale alongside the demand in the last month and are thrilled to be able to serve more patients, customers, and wholesale partners with our newest cultivation facility and equipment,” said Nicholas Vita, CEO, Columbia Care. “As always, we owe a debt of gratitude to the CRC as well as local officials and our communities for their support in our efforts to make New Jersey one of the strongest cannabis markets in the world and a beacon for the industry.”

Both Cannabist locations began adult use sales on April 21 as one of the first seven operators to receive initial approval in the state and have continued to expand their hours. Each dispensary will continue to have medical-only hours, along with medical-only parking spots, pick-up lines and dedicated phone lines to ensure that patient access remains unaffected. Adult use customers will now find an even broader range of edibles, flowers, pre-rolls and vapes as more products are approved through the state’s third-party testing requirement. The menus also include an expanding brand selection, including Columbia Care brands Seed & Strain and Triple Seven, with more planned, pending regulatory approval.

In addition to the new 270,000-square-foot cultivation, manufacturing and processing facility, the Company also operates a 50,000-square-foot facility, also located in Vineland. The Company has a third retail location in development in New Jersey, which is expected to open later in 2022.

For more information on Cannabist locations, hours and menu availability in New Jersey, visit gocannabist.com/newjersey. For more information on Columbia Care, visit col-care.com.

About Columbia Care

Columbia Care is one of the largest and most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 18 U.S. jurisdictions and the EU. Columbia Care operates 131 facilities including 99 dispensaries and 32 cultivation and manufacturing facilities, including those under development. Columbia Care is one of the original multi-state providers of medical cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the company launched Cannabist, its new retail brand, creating a national dispensary network that leverages proprietary technology platforms. The company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including Seed & Strain, Triple Seven, gLeaf, Classix, Press, Amber and Platinum Label CBD. For more information on Columbia Care, please visit www.col-care.com.

Caution Concerning Forward-Looking Statements

This press release contains certain statements that constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable securities laws and reflect the Company’s current expectations regarding future events. Forward-looking statements or information contained in this release include, but are not limited to, statements or information with respect to the Company’s ability to execute on retail, wholesale, brand and product initiatives in New Jersey. These forward-looking statements or information, which although considered reasonable by the Company, may prove to be incorrect and are subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied by any forward-looking information. These risks, uncertainties and other factors include, among others, favorable operating and economic conditions; obtaining and maintaining all required licenses and permits; favorable production levels and sustainable costs from the Company’s operations; and the level of demand for cannabis products, including the Company’s products sold by third parties. In addition, securityholders should review the risk factors discussed under “Risk Factors” in Columbia Care’s Form 10 dated May 9, 2022, filed with the applicable securities regulatory authorities and described from time to time in documents filed by the Company with Canadian and U.S. securities regulatory authorities.

Investor Contact
Lee Ann Evans
Capital Markets
[email protected]

Media Contact
Lindsay Wilson
Communications
+1.978.662.2038
[email protected]

Source: Columbia Care Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
AWH Launches Adult-Use Operations in New Jersey https://mjshareholders.com/awh-launches-adult-use-operations-in-new-jersey/ Tue, 12 Apr 2022 16:07:34 +0000 https://www.cannabisfn.com/?p=2943723

Ryan Allway

April 12th, 2022

News, Top News


AWH is among the first 7 New Jersey operators to serve adult-use consumers

NEW YORKApril 12, 2022 /PRNewswire/ – Ascend Wellness Holdings, Inc. (“AWH” or the “Company”) (CSE: AAWH.U) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator focused on bettering lives through cannabis, today announced it has been approved to serve adult-use consumers in New Jersey.

Ascend Wellness Holdings, Inc. Logo (CNW Group/Ascend Wellness Holdings, Inc.)
Ascend Wellness Holdings, Inc. Logo (CNW Group/Ascend Wellness Holdings, Inc.)

AWH is one of the first operators in the state to commence adult-use sales in the coming weeks starting with its flagship Ascend Rochelle Park dispensary located at 174 NJ-17 N. The Company currently operates two of the state’s 23 medical dispensaries and expects to sell adult-use cannabis products at its Montclair retail location at 395 Bloomfield Ave. and open a third dispensary, located in Fort Lee, later this year.

AWH is also approved by the New Jersey Cannabis Regulatory Commission (“CRC”) to begin adult-use cultivation and manufacturing operations at its Franklin facility, which includes 16,000 square feet of canopy that will reach 100,000 square feet by year-end 2023. Recently, the Company scaled its cultivation capabilities to keep pace with the growing total addressable market projected to exceed $2 billion by 2025. In anticipation of growing consumer demand, AWH has enhanced local hiring initiatives and plans to create new jobs throughout New Jersey.

“It is an honor to be part of the inaugural group of cannabis businesses building the foundation for New Jersey’s adult-use market,” said Abner Kurtin, founder and CEO of AWH. “This is a tremendous milestone in our Company growth, and we look forward to expanding cannabis access to more residents across the state while continuing to provide our patients with top care.”

“AWH has served thousands of patients since entering New Jersey’s medical market in May 2021, and we are equipped to offer the same affordable and safe cannabis experiences to our growing community of adult-use consumers,” said Frank Perullo, president of AWH. “Our knowledgeable retail team at Ascend Rochelle Park is prepared to welcome consumers at every stage of their cannabis journeys and provide personalized guidance for all lifestyles and preferences.”

About AWH:
AWH is a vertically integrated operator with assets in IllinoisMichiganOhioMassachusetts, and New Jersey. AWH owns and operates state-of-the-art cultivation facilities, growing award-winning strains and producing a curated selection of products. AWH produces and distributes Ozone branded products. For more information, visit www.awholdings.com.

Forward-Looking Statements
This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding the plans, intentions, expectations, estimates, and beliefs of the Company. Words such as “expects”, “continue”, “will”, “anticipates” and “intends” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current projections and expectations about future events and financial trends, and on certain assumptions and analysis made by the Company in light of experience and perception of historical trends, current conditions and expected future developments and other factors management believes are appropriate.

Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Such factors include, among others: the risks and uncertainties identified in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and in the Company’s other reports and filings with the applicable Canadian securities regulators and the U.S. Securities and Exchange Commission. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly, readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward-looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
VIVO Cannabis Announces Fourth Quarter 2021 Results https://mjshareholders.com/vivo-cannabis-announces-fourth-quarter-2021-results/ Thu, 31 Mar 2022 16:14:00 +0000 https://www.cannabisfn.com/?p=2942432

Ryan Allway

March 31st, 2022

News, Top News


  • Net revenue for Q4 2021 was $6.9 million; Net revenue for 2021 was $25 million.
  • In February 2021, closed a $7.2 million equity raise to help fund VIVO’s growth
  • In July 2021, the Company elected a new Board of Directors, announced the appointment of Ray Laflamme as CEO and Chairman of the Board and later welcomed the Former President of McCain Foods Canada and CEO of Zenabis Global, and Former CFO of Cronos Group, to the Board of Directors.
  • In July 2021, announced that its EU-GMP licensed subsidiary, Beacon Medical Germany GmbH, received its first import permit from Germany’s BfArM, the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte), allowing for the import of Canadian grown dried flower medical cannabis from the Company’s EU-GMP-certified Napanee, Ontario site, into Europe.
  • In December 2021, recorded first significant revenues of Canadian produced EU-GMP product by VIVO’s German business
  • In mid 2021 the Company refined its strategy and is now focused primarily on medical cannabis
  • The Company continues to have market leadership in Australia and leveraged its Canadian knowledge base to accelerate product efficacy, cannabis medical information sharing, and sales growth
  • With the Company’s EU-GMP certification, it is now in a position to repeat its Australian success in Germany and in other global markets, all of which are exclusively medically focused
  • Over 350% year-over-year sales growth in Australia

Toronto, Ontario–(Newsfile Corp. – March 31, 2022) – VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) (“VIVO” or the “Company“) today released its fourth quarter 2021 financial and operating results.

Management Commentary

“We continue to be laser focused on growth, profitability, and the medical cannabis channels in Canada and Internationally,” said Ray Laflamme, CEO of VIVO. “The Board recently approved our 2022 Business Plan in which we are targeting significant international growth along with continued success in domestic markets. We look forward to striving to achieve industry leading metrics as we track our progress towards meeting our objectives. We are confident that VIVO will continue to strengthen its core businesses in 2022.”

Financial Summary

Net revenue for the fourth quarter of 2021 was $6.9 million which represents an 11% increase quarter-over-quarter as compared to Q3 2021. This increase is primarily due to increased sales to Australia balanced by modest decreases in adult-use sales reflecting the Company’s change in focus away from the adult-use recreational market.

Net revenue for 2021 was $25 million, a decrease of about 24% compared with the same period last year, driven largely by a decrease in adult-use sales and a shift in focus to domestic and international medical channels.

General and administrative expenses decreased to $14.3 million for the year ended December 31, 2021, compared to $18.7 million for 2020. The decrease was primarily driven by a reduction in salaries and wages of $3.2 million and a reduction in consulting and professional fees of $1 million.

The Company’s Adjusted EBITDA increased by $1.1 million to a loss of $11.1 million during the year ended December 31, 2021 compared with the same prior year period, mainly due to lower operating expenses.

During the year-end audit, an annual asset impairment test was performed, and the Company determined an impairment charge of $71.5 million was required as Canna Farms’ carrying value was found to exceed its recoverable amount. This was offset by a reduction in the Company’s deferred tax liability of $18.2 million.

Key Performance Indicators

KPI (P&L amounts in millions) Q4 2021 Quarter-over-Quarter Change Q3 2021
Net Revenue $6.9 +11% $6.2
SG&A $3.1 (9%) $3.4
Adjusted EBITDA (1) ($3.7) NMF ($2.1)
Cash and equivalents $11.3 (9%) $12.4


(1) 
Adjusted EBITDA is not a measure of financial performance under IFRS. For the Company’s definition of Adjusted EBITDA, see the Company’s management’s discussion and analysis for the year-ended December 31, 2021, available under the Company’s profile at www.sedar.com.

Business Update

General and administrative expenses decreased by 24% for the year ended December 31, 2021, compared to 2020. Sales and marketing expenses decreased by 15% in 2021, reflecting the reallocation of external sales agency costs internally and focusing on medical cannabis growth. Finance expenses decreased during the year ended December 31, 2021, by 75% compared to the same period in 2020 driven by the Company eliminating its $5.3 million of convertible debentures, resulting in a decrease in accretion and interest expenses on the debt.

The Company had gains (losses) on other financial assets, comprised of marketable securities of other issuers held by the Company. In 2021 the Company realized gains of $1.0 million on these assets and proceeds from the sale of these financial assets of $8.2 million. During the year, the Company raised $7.2 million of equity (net of listing fees). In 2021, the Company also generated proceeds of $1.0 million from the sale of property. As of December 31, 2021, the Company had working capital of $18.3 million including cash and cash equivalents of $11.3 million.

In July 2021, at the Annual General Meeting, the shareholders elected Holly Workman and Eric Shipman as new Directors to the Board, announced the appointment of Ray Laflamme, founder of Canna Farms, as CEO and Chairman of the Board and in December 2021, appointed Glen A. Huber, former CFO of Cronos Group and Shai Altman, former President of McCain Foods and former CEO of Zenabis Global, to the Board of Directors.

Strategic Priorities

VIVO remains focused on executing against its strategic priorities and focusing on the medical cannabis market in Canada and internationally. The Company has made significant progress in enhancing supply and production capabilities, expanding its customer network, increasing its focus on providing patient focused medical cannabis products and services, and accelerating its international medical business. VIVO believes focusing on its core priorities will generate long-term shareholder value and accelerate the path to profitability.

Patient Care Expertise

The Company has provided educational consultants and medical cannabis care in over 150,000 patient interactions through its HMED clinics (as defined below) since 2017. Canna Farms’ best-in-class, award-winning, Patient Care Team has been providing patient services since 2014 and has firsthand expertise in product ordering, and patient support. With patient-centricity at its core, in 2021 the Company widened its product offerings and enhanced its best-in-class support programs including Compassionate Care, Veterans, and First Responders, so that all patients have access to affordable quality cannabis as medicine.

Quality Production

Canna Farms and ABcann Medicinals together have more than fifteen years of experience supporting cannabis medical patients with a wide range of conditions and symptoms and together have amassed a deep understanding of patient motivations and needs.

Canna Farms was established in 2013, as the first licensed producer in British Columbia, and since that time has established deep roots in the medical cannabis community. It is now a respected and recognized cannabis brand with thousands of positive patient self-reported outcomes. Today Canna Farms is one of the top medical brands in Canada. Canna Farms was BC’s first licensed producer and proudly holds itself to the highest cultivation standards. In 2020, it was recognized by Brightfield Group as the brand with the 4th highest Brand Awareness.

Canna Farm has many thousands of patients who have tracked themselves and self-reported their outcomes using the Strainprint app in over 650,000 sessions. Due to this, Canna Farm has the largest data set within the mobile app and the efficacy of specific strains used for various conditions have been published in several independent academic peer-reviewed articles. Canna Farms operates an industry-leading online medical cannabis platform, (https://www.cannafarms.ca/product-medical) that combines the Company’s brands with products from third-party cultivators in one on-line medical store. There are currently over 10 brands and 100 curated products offered on the Canna Farms medical store.

Canna Farms operations focus on indoor cannabis cultivation, packaging, solventless extraction and concentrate production.

ABcann Medicinals’ operations in Napanee Ontario focus on ethanol extraction, product formulation, and EU-GMP related processes. This operation’s ethanol extraction suite produces high quality cannabis extracts and distillates for use in many of VIVO’s products including quality oils, distillates, concentrates and more advanced formulations of VIVO’s current and anticipated portfolio of medical products, as well as edibles and topicals.

With all operating facility expansion projects completed, VIVO anticipates capital expenditures for 2022 to be minimal. Disciplined investments in product development, facility optimization and international market commercialization are expected to continue to facilitate future profitable growth.

International Markets

VIVO continues to pursue its international expansion strategy, leveraging its experience and leadership to enter new high-growth markets. The Company’s initial focus is on the German and Australian markets, which, combined, have a population of over 100 million people.

The Company has a strong medical cannabis market leadership established in Australia and leverages its Canadian knowledge base to accelerate product efficacy, cannabis medical information sharing, and sales growth in that market. Australia’s Therapeutics Goods Administrator (“TGA”) continues to report a record number of new patient approvals and the growth in the market has been matched by the growth in VIVO’s Beacon Medical Australia business. VIVO currently sells five products under the Beacon Medical brand in Australia.

On March 11, 2021, VIVO’s Vanluven facility in Napanee, Ontario received EU-GMP (European Union Good Manufacturing Practices) certification from Germany’s Brandenburg health authority, the Landesamt für Arbeitsschutz, Verbraucherschutz und Gesundheit (“LAVG”). The certification enables VIVO, through its ABcann Medicinals subsidiary, to export product for sale into European and other markets requiring products to be manufactured under EU-GMP standards.

On July 29, 2021, the Company announced that its EU-GMP licensed subsidiary, Beacon Medical Germany GmbH, received its first import permit from Germany’s BfArM, the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte), allowing for the import of Canadian grown dried flower medical cannabis from the Company’s GMP-certified Napanee, Ontario site, into Europe.

Starting October 2021, the Company, through its ABcann Medicinals subsidiary, exported EU-GMP dry flower to Germany. This was an enormous milestone for the Company.

With the Company’s recent EU-GMP certification, it is now in a position to repeat its Australian success in Germany and in other global markets, all of which are exclusively medically focused. The Company’s products and brands prove their value in Canada first, and this success is then replicated in international markets, as regulations allow.

Clinical Care

The Company purchased its Harvest Medicine (“HMED”) operations in 2018 and since the acquisition has leveraged clinical insights from tens of thousands of HMED patients to research patient outcomes, to publish observational clinical studies, to educate and increase health care prescriber adoption, to improve market access, and to direct future product development within its medical channels. Harvest Medicine utilizes a virtual platform, “HMED Connect” and has recently added pharmacy consultations as a service for patients as part of their medical cannabis care offering.

The portfolio consists of four education-focused, patient-centric, cannabis discovery clinics, including two clinics located in Alberta and two additional clinics in the provinces of New Brunswick and Nova Scotia. HMED has conducted more than 150,000 registered patient visits through its clinics, clinic-in-clinic partnerships and via its telemedicine platform, making it one of the top clinic networks in Canada. In the first half of 2021, Harvest Medicine began offering pharmacy consultations as an additional service offering for patients as part of their medical cannabis care.

VIVO is committed to pursuing innovation throughout its value chain. The Company uses data insights gained from Harvest Medicine’s clinics and from Canna Farms’ medical cannabis platform as a foundation for the development of products that more effectively meet patients’ needs.

During 2021 the Company had to temporarily suspend in-clinic visits at its Harvest Medicine clinics (the majority of these have been reopened). The Company’s HMED Connect telemedicine platform proved to be of increased service to the medical cannabis market with patients preferring to conduct appointments online during the pandemic. HMED’s telemedicine platform brings medical cannabis information and services to patients across Canada, allowing them to access the same patient-centric services they would receive in HMED clinics, online.

About VIVO Cannabis®

VIVO Cannabis® is recognized for trusted, premium cannabis products and services. It holds production and sales licences from Health Canada and operates world-class indoor and seasonal airhouse cultivation facilities. VIVO has a collection of premium brands, each targeting different customer segments, including Canna Farms™, Beacon Medical®, Fireside™, and Lumina™. Harvest Medicine™, VIVO’s patient-centric, scalable network of medical cannabis clinics, has serviced over 150,000 patient visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia. For more information visit: www.vivocannabis.com

For further information:

VIVO Investor Relations
Michael Bumby, Chief Financial Officer
[email protected]

Instagram: https://www.instagram.com/vivo_cannabis/
LinkedIn: https://www.linkedin.com/company/vivo-cannabis-inc/
Facebook: https://www.facebook.com/vivocanna/
Twitter: https://twitter.com/vivo_cannabis

Disclaimer for Forward-Looking Information

All dollar amounts in this news release are in Canadian dollars. Certain statements in this news release are forward-looking statements, which are statements that are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of VIVO and its management regarding the future. Forward-looking statements in this news release include statements regarding: the Company’s expected catalysts to deliver profitable growth, including entry into domestic and international markets; the development and launch of innovative products and services and the financial impact thereof; the integration of its facilities; redefining the Company’s strategy; accelerating its path to profitability; the Company’s expectation that focusing on the medical cannabis segment will generate long-term shareholder value and accelerate the path to profitability; the factors that VIVO believes will drive significant growth in medical cannabis utilization; and the ability of the Company’s growth initiatives to drive future profitable sales beyond 2021. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward‐looking statements, including: that the medical cannabis market may not grow to the extent, within the time, or for the reasons expected by the Company; changes to the recreational market; that the COVID‐19 pandemic may last longer and have a more significant impact on the Company’s operations, the Canadian cannabis industry, or the global economy generally, than currently expected; that the Company faces competition against new market entrants and participants; that the Company may not be able to launch new products in the time expected or at all and that patients may not receive the expected benefits therefrom; that the Company may not be able to achieve competitive margins; that new products, if launched, may not be accepted by the market or may become subject to product liability claims; that the Company may not be able to obtain necessary licences; that demand for the Company’s products may not meet management’s expectations; that the Company may be unable to retain its key talent; that the Company may not be able to execute on its strategic partnerships; that the Company may not obtain any other necessary regulatory approvals as required from time to time; that the Company may be unable to protect its intellectual property; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward‐looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully, and the more extensive risk factors included in the Company’s management’s discussion and analysis for the year-ended December 31, 2021, which is available on SEDAR, in evaluating the forward‐looking statements contained in this news release, and are cautioned not to place undue reliance on such forward‐looking statements, which are qualified in their entirety by these cautionary statements. The forward‐looking statements in this news release are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any such forward‐looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
IM Cannabis Reports Record Preliminary Fourth Quarter and Full Year 2021 Financial Results https://mjshareholders.com/im-cannabis-reports-record-preliminary-fourth-quarter-and-full-year-2021-financial-results/ Thu, 10 Mar 2022 17:36:21 +0000 https://www.cannabisfn.com/?p=2940215

Ryan Allway

March 10th, 2022

News, Top News


Q4 2021 revenues expected to be at least $20 million, an increase of at least 308% year-over-year and at least 37% sequentially

Full Year 2021 revenues expected to increase at least 240% year-over-year to at least $54 million

TORONTO and GLIL YAM, IsraelMarch 10, 2022 /PRNewswire/ — IM Cannabis Corp. (the “Company“, “IM Cannabis“, or “IMC”) (CSE: IMCC) (NASDAQ: IMCC), a leading medical and adult-use recreational cannabis company with operations in IsraelCanada, and Germany, provided preliminary unaudited financial results for the three months and fiscal year ended December 31, 2021. All amounts are reported in Canadian dollars unless otherwise stated.

IM Cannabis Logo
IM Cannabis Logo

Preliminary Q4 and Full Year 2021 Financial & Operational Highlights:

  • Preliminary revenues for Q4 2021 were at least $20 million, representing an approximate increase of at least 37% from Q3 2021 and at least 308% compared to the same prior-year period.
  • Preliminary gross margin before fair value adjustment was at least 18% in Q4 2021, temporarily impacted by modest investments in the German market and impact of COVID-19 restrictions in Canada that disrupted labour and supply chains.
  • Preliminary revenues for fiscal year 2021 were at least $54 million, representing an approximate increase of at least 240% from fiscal year 2020. Preliminary gross margin before fair value adjustment was at least 22% in fiscal year 2021.
  • Focus Medical Herbs Ltd. (“Focus Medical“) successfully imported approximately 399 kilograms of premium, indoor-grown, Canadian dried cannabis following approval from the Ministry of Agriculture to import to the Israeli market in Q4 2021. Subsequent to Q4 2021, the WAGNERS brand was launched in Israel.
  • In Q4 2021, the Company announced the anticipated 2022 launch of WAGNERS brand in the rapidly evolving German medical cannabis market.
  • Signed a definitive agreement in Q4 2021 to acquire Oranim, Jerusalem’s leading medical cannabis pharmacy, positioning IMC as one of the largest retailers of medical cannabis in Israel. The acquisition of Oranim is conditional upon receipt of all requisite approvals, including regulatory approval from the Israeli Medical Cannabis Agency. The closing of the Oranim acquisition is expected by the end of Q2 2022.

Management Commentary

“We built significant momentum across our operating platform in 2021, as evidenced by our annual revenues growth of at least 240% to a record of at least $54 million,” said Oren Shuster, Chief Executive Officer of IMC. “In Israel, we have become among the largest distributors of medical cannabis and are well positioned to capture market growth today and in the future with the potential for recreational legalization. We continue to capture meaningful market share in the premium segment in Canada driven by our staunch focus on cultivation excellence and increasing brand recognition of WAGNERS and Highland Grow. Importantly, our execution with our recreational and medical operations in Canada and Israel and our global distribution expertise provides us with the blueprint to effectively capitalize on the substantial German market opportunity as it liberalizes its cannabis laws.”

“As we move through 2022, we remain focused on realizing synergies across our supply chain while scaling operations in the three largest federally legal markets where we currently operate, which makes IMC uniquely positioned to emerge as the leading purveyor of premium cannabis on a global scale. I look forward to providing further updates to the market during our upcoming earnings call later this month,” concluded Shuster.

The information provided within this release should be read in conjunction with the Company’s audited consolidated financial statements for the year and three months ended December 31, 2021 (the “Audited Financial Statements“), and the accompanying management’s discussion and analysis for the year and three months ended December 31, 2021, which will be filed on the Company’s SEDAR profile at www.sedar.com.

About IM Cannabis Corp.

IM Cannabis (NASDAQ: IMCC) (CSE: IMCC) is a leading international cannabis company providing premium products to medical patients and adult-use recreational consumers. IM Cannabis is one of the very few companies with operations in IsraelGermany, and Canada, the three largest federally legal markets. The ecosystem created through its international operations leverages the Company’s unique data-driven perspective and product supply chain globally. With its commitment to responsible growth and financial prudence, and the ability to operate within the strictest regulatory environments, the Company has quickly become one of the leading cultivators and distributors of high-quality cannabis globally.

The IM Cannabis ecosystem operates in Israel through its commercial relationship with Focus Medical, which cultivates, imports, and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centres and logistical hubs in Israel that enable the safe delivery and quality control of IM Cannabis products throughout the entire value chain. In Germany, the IM Cannabis ecosystem operates through Adjupharm GmbH (“Adjupharm“), where it also distributes cannabis to pharmacies for medical cannabis patients. In Canada, IM Cannabis operates through Trichome Financial Corp. (“Trichome“) and its subsidiaries Trichome JWC Acquisition Corp. (“TJAC“) and MYM Nutraceuticals Inc. (“MYM“), where it cultivates and processes cannabis for the adult-use market at its OntarioNova Scotia, and Quebec facilities under the WAGNERS and Highland Grow brands. For more information, please visit www.imcannabis.com.

Disclaimer Regarding Financial Information

The financial information presented in this press release is based on preliminary, unaudited financial statements prepared by management, for the fourth quarter and fiscal year ended December 31, 2021. Accordingly, such financial information may be subject to change. While the Company does not expect there to be any material changes to the financial information presented in this press release, to the extent that it is inconsistent with the information contained in the Audited Financial Statements, the financial information contained in this news release shall be deemed to be modified or superseded by such Audited Financial Statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws.

Disclaimer for Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian and United States securities laws (collectively, “forward-looking information“). Forward-looking information are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking information in this press release includes, without limitation, statements relating to the financial results of the Company for the fourth quarter of 2021 and the fiscal year ended December 31, 2021, the resumption of growth in IsraelGermany and Canada since the end of the fourth quarter of 2021, expected revenues drivers in the first quarter of 2022, the ability of the Company to continue to capture meaningful market share in the premium segment of the Canadian cannabis market, expectations about financial performance of the Company’s Canadian operations in the first quarter of 2022, the ability of the Company to achieve growth in the German medical cannabis market and the Company’s emerging position as a leading purveyor of premium cannabis on a global scale.

Forward-looking information is based on assumptions that may prove to be incorrect, including but not limited to the ability of the Company to execute its business plan and the continued growth of the medical and/or recreational cannabis markets in the countries in which the Company operates or intends to operate, the Company maintaining “de facto” control over Focus Medical in accordance with IFRS 10, Focus Medical maintaining its existing Israeli medical cannabis propagation and cultivation licenses and the expected decriminalization and/or legalization of adult-use recreational cannabis in Israel. The Company considers these assumptions to be reasonable in the circumstances. However, forward-looking information is subject to business and economic risks and uncertainties and other factors that could cause actual results of operations to differ materially from those expressed or implied in the forward-looking information. Such risks include, without limitation: any failure of the Company to maintain “de facto” control over Focus Medical, Focus Medical maintaining its existing Israeli medical cannabis propagation and cultivation licenses; any determination that the Company is directly engaging in the Israeli medical cannabis market; the ability of the Company to comply with applicable government regulations in a highly regulated industry; unexpected changes in governmental policies and regulations affecting the production, distribution, manufacture, import, export or use of medical and/or recreational cannabis, as applicable, in IsraelCanada and Germany; any unexpected failure of any of Focus Medical, TJAC or MYM to maintain in good standing or renew all required licenses, permits or authorizations to conduct cannabis activities in their respective jurisdictions; the ability of the Company, its subsidiaries and Focus Medical to maintain primary and ancillary business licenses, permits and approvals; the Company and Focus Medical having to rely on third party cannabis producers to supply Adjupharm and Focus Medical with product to successfully fulfill previously announced sales agreements and purchase commitments; any unexpected failure of any of Focus Medical, Adjupharm, Trichome or MYM to maintain in good standing or renew all required licenses, permits or authorizations to conduct cannabis activities in their respective jurisdictions; reliance on the Company’s commercial facilities in Germany and Canada and Focus Medical’s commercial facilities in Israel to conduct medical cannabis activities and any unexpected failure of the Company, its subsidiaries or Focus Medical to maintain such commercial facilities in good standing with all applicable regulations, including all required licenses and permits; any adverse consequences as a result of certain legal proceedings initiated by Israeli municipal authorities against Focus Medical, Oren Shuster, and certain other shareholders and stakeholders of Focus Medical (the “Construction Proceedings“); unexpected disruptions to the operations and businesses of the Company and/or Focus Medical as a result of the COVID-19 global pandemic or other disease outbreaks including a resurgence in the number of cases of COVID-19, and the ongoing uncertainty that could result in restrictions to contain the virus being re-imposed or imposed on a more strict basis, including restrictions on movement and businesses; unexpected consequences that may arise if Focus Medical were to lose its designation as an essential service in the State of Israel during any current or resurgent COVID-19 outbreak; the extent to which COVID-19 impacts the global economy; the success of new COVID-19 workplace policies and the ability of people to return to workplaces inconsistent public opinion and perception regarding the use of cannabis; perceived effects of medical cannabis products; and the Company’s ability to maintain or improve the brand position of the IM Cannabis brand in the Israeli medical cannabis markets.

Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s management’s discussion and analysis dated November 15, 2021 and annual information form dated April 26, 2021 filed with Canadian securities regulators and which are available on the Company’s issuer profile on SEDAR at www.sedar.com. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Non-IFRS Measure

This press release includes reference to “Gross Margin”, which is a non-International Financial Reporting Standards (“IFRS“) financial measure. Non-IFRS measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS, and are therefore unlikely to be comparable to similar measures presented by other companies. The Company defines gross margin as the difference between revenues and cost of goods sold divided by revenues (expressed as a percentage), prior to the effect of a fair value adjustment for inventory and biological assets. IM Cannabis has used or included this non-IFRS measure solely to provide investors with added insight into IM Cannabis’s financial performance. Readers are cautioned that such non-IFRS measure may not be appropriate for any other purpose. Non-IFRS measures should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

Three months ended December 31, 2021 December 31, 2020
Revenues $ 20,250 $ 4,900
Cost of goods sold $ 16,550 $ 2,109
Gross profit before FV adjustments $ 3,700 $ 2,791
Gross margin before FV adjustments 18% 57%

Logo – https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

Company Contact:
Maya Lustig, Director Investor & Public Relations
IM Cannabis
+972-54-677-8100
[email protected]

Investor Relations:
Brooks Hamilton, Director
MZ Group – MZ North America
+1 949-546-6326
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
FIRE & FLOWER announces filing of form 40-F with sec as company prepares for nasdaq listing https://mjshareholders.com/fire-flower-announces-filing-of-form-40-f-with-sec-as-company-prepares-for-nasdaq-listing/ Wed, 19 Jan 2022 16:54:20 +0000 https://www.cannabisfn.com/?p=2936648

Ryan Allway

January 19th, 2022


TORONTOJan. 19, 2022 /CNW/ – Fire & Flower Holdings Corp. (“Fire & Flower” or the “Company“) (TSX: FAF) (OTCQX: FFLWF), a leading, technology-powered, cannabis retailer, today announced the filing of its Form 40-F Registration Statement (“Form 40-F“) with the United States Securities and Exchange Commission (the “SEC“), in preparation for the Company to list its shares on The Nasdaq Stock Market LLC (“Nasdaq“).  A copy of the Form 40-F is available on the Company’s website at www.fireandflower.com or the SEC website at www.sec.gov.

“Fire & Flower’s anticipated listing on the Nasdaq is strategically aligned with our expanded digital e-commerce offering and its planned entry into the U.S. cannabis market,” said Trevor Fencott, Chief Executive Officer of Fire & Flower. “We have quickly demonstrated the success of our technology-driven retail model in Canada’s cannabis market, becoming the first company to build a true cannabis consumer technology platform. Listing on the Nasdaq will allow us to expand our shareholder base and drive increased shareholder value as we continue to leverage our unique technology-driven business model to enter new targeted markets across North America. We are excited to share our vision for ‘smart’ cannabis retail to a broader audience of investors.”

Listing of the Company’s common shares on Nasdaq remains subject to the approval of Nasdaq and the satisfaction of all applicable listing and regulatory requirements, including the effectiveness of the Form 40-F. Following receipt of all required approvals, the Company will issue a press release announcing its first trading date on Nasdaq. Fire & Flower’s common shares will continue to trade on the OTCQX under the ticker symbol FFLWF until the commencement of trading on the Nasdaq. Fire & Flower’s common shares will continue to trade on the Toronto Stock Exchange under the ticker symbol “FAF” following the completion of the proposed Nasdaq listing.

About Fire & Flower

Fire & Flower is a leading, technology-powered, adult-use cannabis retailer with more than 100 corporate-owned stores in its network. The Company leverages its wholly-owned technology development subsidiary, Hifyre, to continually advance its proprietary retail operations model while also providing additional independent high-margin revenue streams. Fire & Flower guides consumers through the complex world of cannabis through education-focused, best-in-class retailing while the Hifyre digital retail and analytics platform empowers retailers to optimize their connections with consumers. The Company’s leadership team combines extensive experience in the technology, cannabis and retail industries.

Through the strategic investment of Alimentation Couche-Tard Inc. (owner of Circle K convenience stores), the Company has set its sights on global expansion as new cannabis markets emerge and is poised to expand into the United States when permitted through its strategic licensing agreement with Fire & Flower U.S. Holdings upon the occurrence of certain changes to the cannabis regulatory regime.

Fire & Flower is a multi-banner cannabis retail operator that owns and operates the Fire & Flower, Friendly Stranger, Happy Dayz and Hotbox brands. Fire & Flower Holdings Corp. owns all issued and outstanding shares in Fire & Flower Inc. and Friendly Stranger Holdings Corp., licensed cannabis retailers that own and operate cannabis retail stores in the provinces of British ColumbiaAlbertaSaskatchewanManitobaOntario, and the Yukon territory.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains certain forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate”, “achieve”, “could”, “believe”, “plan”, “intend”, “objective”, “continuous”, “ongoing”, “estimate”, “outlook”, “expect”, “project” and similar words, including negatives thereof, suggesting future outcomes or that certain events or conditions “may” or “will” occur. These statements are only predictions.

Forward-looking statements are based on the opinions and estimates of management of Fire & Flower at the date the statements are made based on information then available to the Fire & Flower. Various factors and assumptions are applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements. Forward-looking statements are subject to and involve a number of known and unknown, variables, risks and uncertainties, many of which are beyond the control of Fire & Flower, which may cause Fire & Flower’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Such factors, among other things, include: regulatory and other approvals or consents; fluctuations in general macroeconomic conditions; fluctuations in securities markets; the impact of the COVID-19 pandemic; the ability of the Company to successfully achieve its business objectives and political and social uncertainties.

No assurance can be given that the expectations reflected in forward-looking statements will prove to be correct. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form dated April 30, 2021 and the heading “Risks and Uncertainties” in the management discussion and analysis for the quarter ended October 30, 2021 filed on its issuer profile on SEDAR at www.sedar.com . The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

SOURCE Fire & Flower Holdings Corp.

For further information: To learn more about Fire & Flower, visit www.fireandflower.com.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
High Life Farms Launches Best-Selling Nuggies in California, The Largest Cannabis Market in the U.S. https://mjshareholders.com/high-life-farms-launches-best-selling-nuggies-in-california-the-largest-cannabis-market-in-the-u-s/ Tue, 26 Oct 2021 23:16:23 +0000 https://www.cannabisfn.com/?p=2935688

Ryan Allway

October 26th, 2021


High Life Farms (“HLF”), a privately held, multi-state, vertically integrated cannabis company with operations in Michigan and California, today announced that its best-selling line of Nuggies chocolate-covered pretzel edibles is now available in California. The product expansion marks a major milestone for HLF, which is bringing its fan-favorite, high-quality in-house edible products to California for the first time.

“We’ve highly anticipated the expansion of our Nuggies line of chocolate edibles to California since our original launch in Michigan, and we’ve worked diligently to find the best suppliers to ensure we are producing the same high-quality products that meet our standards,” said Vinnie Celani, Co-founder of High Life Farms. “Nuggies have experienced huge success in Michigan and are one of our best-selling products. We’re thrilled to roll out our unique line of infused pretzel bites to consumers in the country’s biggest cannabis market and hope they enjoy them as much as our customers in Michigan.”

Nuggies have been one of the top-selling cannabis-infused chocolate products in Michigan since its initial launch in April 2021, according to LeafLink. Nuggies are be available across dispensaries in California including Barbary Sunset, IVTHC, Bare and others, as well as for delivery in three flavors:

  • Chocolate Peanut Butter: The original Nuggies flavor; creamy chocolate and peanut butter coat crunchy pretzel balls that are lightly dusted with salt for the perfect combination of salty and sweet.
  • Strawberries and Cream: Milk and white chocolate coating infused with strawberry flavoring surrounding a crunchy pretzel core for a familiar and beloved flavor combination.
  • Peanut Butter and Banana: Creamy chocolate and peanut butter infused with banana flavoring coating crunchy pretzel balls, lightly dusted with salt for a nostalgic, salty-sweet flavor blast.

Edibles products are gaining popularity across U.S. cannabis markets, expecting to total more than $2 billion in sales this year, and will reach nearly $3 billion in 2022 according to Seattle-based data analytics company Headset. Sales are expected to continue to rise  as new-to-cannabis consumers enter the market. HLF’s expansion of Nuggies into California will help meet rising consumer demand for cannabis-infused edibles products.

For more information, visit https://highlifefarms.com/.

About High Life Farms
High Life Farms is a national privately held, vertically integrated cannabis company based in Michigan with operations in the world’s largest cannabis market: California. High Life Farms’ best-in-class portfolio includes cultivation, manufacturing, distribution, in-house brands, brand partnerships, white labeling solutions and ownership stakes in numerous dispensaries. The company believes in the cannabis plant’s potential to improve health, wellness, happiness and that everyone should have the right to make choices that improve their personal wellbeing. For more information, visit https://highlifefarms.com/.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
SpeakEasy’s Indoor Flower, Extracts and Pre-Rolled Joints Fully Sold Out https://mjshareholders.com/speakeasys-indoor-flower-extracts-and-pre-rolled-joints-fully-sold-out/ Sat, 26 Jun 2021 16:13:14 +0000 https://www.cannabisfn.com/?p=2924339

Ryan Allway

June 26th, 2021


ROCK CREEK, BCJune 26, 2021 /CNW/ – SpeakEasy Cannabis Club Ltd. (CSE: EASY) (Frankfurt: 39H) (the “Company” or “SpeakEasy“) a holder of a federal licence to cultivate, process and sell cannabis under the Cannabis Act is excited update its shareholders on the progress of its pre-rolled joints production and sales.

SpeakEasy has achieved its projected maximum production of its indoor flower, extracts and pre-rolled joints and is fully sold out for the foreseeable future.

SpeakEasy is excited to report on the progress of its product and sales. The Company has achieved its projected maximum production of its indoor flower, extracts and pre-rolled joints and is fully sold out for the foreseeable future. Our partner, RC Frontier Labs Ltd, recently received state of the art equipment, valuing over approximately CAD $300,000 and expects it to be fully operational in early July.   Pursuant to our agreement with Frontier, this provides the ability to increase production and more than quadruple the Company’s current production capacity for extracts. Demand has exceeded management’s expectations and efforts are being made to increase production to keep up.

Founder Marc Geen states, “We are in the enviable position of having our product in such high-demand whereby we can’t keep up. Our indoor flower is completely sold out and all indoor harvests are spoken for until the end of our forecast period, approximately 3 months. Our extraction lab is running triple shifts, seven days a week and its production is completely sold out, in addition, our pre-rolled joints are also sold out. It’s a great problem to have and is a testament to our foundational beliefs, providing high quality products at reasonable prices will attract and keep customers. We are working hard to increase production across the board and making great strides, a necessity as we are aiming to enter multiple provinces in the near future that we expect, will vastly increase sales”.

Price and Quality

Speakeasy has been able to take its high-quality, economical input material, combined it with in-house processing and packaging and create a product that can be aggressively priced to compete at levels on par or below any currently in industry, all while maintaining a healthy profit margin. Research shows the pre-roll segment of the market has been steadily increasing month over month and is projected to continue growth[1].  SpeakEasy is positioned to be a strong competitor in all provinces with its current sales showing a demand that has exceeded management’s expectations.

About SpeakEasy Cannabis Club Ltd.

SpeakEasy Cannabis Club Ltd. holds a cultivation, processing and sales licence issued by Health Canada under the Cannabis ActSpeakEasy owns 290 acres of land in Rock Creek, British Columbia, and leverages five generations of farming experience in B.C. as well as its favourable location to grow and process high-quality cannabis products at low cost. SpeakEasy cultivates small batch, high quality craft cannabis at scale in a portion of its 63,200 square foot indoor cannabis complex and has completed its harvest of its 60-acre outdoor field. Total yearly production of cannabis flower and biomass is projected to be in excess of 70,000 kilograms per year once in full production.

On behalf of the Board of the Directors

Forward Looking Statement

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause SpeakEasy’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Forward-looking statements in this document include statements concerning SpeakEasy’s expectations concerning the new equipment, orders and the anticipated timing of receipt of such equipment and the impact such equipment will have on production capacity; its expectations regarding its ability to be a strong competitor and its intent to produce and sell high quality craft cannabis, and all other statements that are not statements of historical fact.

Although SpeakEasy believes the forward-looking information contained in this news release is reasonable based on information available on the date hereof, by their nature forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such statements.

Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with general economic conditions; COVID-19, adverse industry events; future legislative and regulatory developments involving cannabis; the Company’s ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the cannabis and hemp industries and markets in Canada and generally; the demand for CBD distillate, cannabis and cannabis related products, the ability of SpeakEasy to implement its business strategies; competition; the ability of SpeakEasy to obtain and retain all applicable licences under the Cannabis Act and other assumptions, risks and uncertainties.

THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS NEWS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS NEWS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.

The Canadian Securities Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>